罗莫索单抗对高基线骨折风险患者的骨折疗效更佳:FRAME研究第一年的事后分析
本研究为FRAME研究第一年的事后分析,采用意向性治疗(ITT)方法,探讨基线FRAX®骨折概率与罗莫索单抗疗效的交互作用。结果显示,与安慰剂相比,罗莫索单抗在基线骨折风险较高的患者中,对临床骨折、骨质疏松性骨折和主要骨质疏松性骨折的疗效显著更佳。
要点
- 罗莫索单抗第一年降低所有骨折结局,临床椎体骨折降幅达80%(p=0.038)。
- 临床骨折、骨质疏松性骨折和MOF的疗效与基线FRAX®概率存在显著交互(p=0.064-0.084)。
- 排除椎体骨折后,非椎体骨折与基线FRAX®概率的交互作用更强(p=0.036-0.046)。
核心结论
- 罗莫索单抗对临床骨折、骨质疏松性骨折和主要骨质疏松性骨折的疗效在基线骨折风险较高的患者中显著更佳。
研究设计与样本
- FRAME研究(NCT01575834)安慰剂对照第一年的事后分析,采用ITT方法,使用Poisson回归扩展分析治疗与FRAX® 10年主要骨质疏松性骨折概率(不包含BMD)及首次骨折风险的关系(调整年龄和随访时间)。
主要发现
- 与安慰剂相比,罗莫索单抗第一年降低所有骨折结局,范围从主要骨质疏松性骨折降低32%(p=0.07)到临床椎体骨折降低80%(p=0.038)。
- 临床骨折、骨质疏松性骨折和主要骨质疏松性骨折的复合结局与基线FRAX®概率存在显著交互作用(p=0.064-0.084),但椎体骨折无显著交互(p>0.3)。
- 在FRAX®概率第25百分位,罗莫索单抗降低所有临床骨折22%,而在第75百分位降低41%。
- 排除椎体骨折后(仅非椎体骨折),与基线FRAX®概率的交互作用更强(p=0.036-0.046)。
关键数值与推荐
- 治疗与FRAX®交互作用的双侧p值<0.1被认为显著。
临床怎么用
- 对于基线骨折风险较高的患者,罗莫索单抗的骨折预防疗效可能更大,可优先考虑用于高FRAX®概率患者。
局限性
- 本研究为事后分析,结果需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: This study aimed to determine the interaction between baseline FRAX® fracture probability and romosozumab efficacy. Using an ITT approach, it was determined that the efficacy of romosozumab on clinical fracture, osteoporotic fracture, and major osteoporotic fracture is significantly greater in patients at high baseline fracture risk, when compared with placebo. INTRODUCTION: Post hoc analyses of placebo-controlled osteoporosis treatment studies have shown significantly greater reductions of fracture incidence for higher fracture risk patients. This study determined the interaction between baseline FRAX® fracture probability and romosozumab efficacy in the placebo-controlled first year of the phase 3 FRAME study (NCT01575834). METHODS: Using an ITT approach, an extension of Poisson regression analysis studied the relationship between treatment, FRAX® 10-year probability of major osteoporotic fracture (MOF, calculated without BMD) and risk of first incident fracture (adjusting for age and follow-up time). Treatment interactions considered outcomes of all clinical fractures, osteoporotic fractures, MOF, clinical vertebral fractures, and morphometric vertebral fractures. Two-sided p value of < 0.1 for the interaction between treatment and FRAX® was considered significant. RESULTS: Compared with placebo, romosozumab reduced the incidence of all fracture outcomes in the first year (range: 32% reduction in MOF [p = 0.07] to 80% reduction in clinical vertebral fractures [p = 0.038]). Significant interactions were observed between efficacy and baseline FRAX® probability for composite outcomes of clinical fractures, osteoporotic fractures, and MOF (p = 0.064-0.084), but not vertebral fractures (p > 0.3). For example, romosozumab decreased all clinical fractures by 22% at the 25th centile of FRAX® probability but the reduction was 41% at the 75th centile. Exclusion of vertebral fractures from each composite fracture outcome (i.e. only nonvertebral fractures included) showed even stronger interactions with baseline FRAX® probability (p = 0.036-0.046). CONCLUSIONS: Efficacy of romosozumab on clinical fracture, osteoporotic fracture, and MOF is significantly greater in patients at high baseline fracture risk compared with placebo.
引用
- McCloskey EV, Johansson H, Harvey NC, et al. Romosozumab efficacy on fracture outcomes is greater in patients at high baseline fracture risk: a post hoc analysis of the first year of the frame study. Osteoporos Int. 2021. PMID: 33537844. doi:10.1007/s00198-020-05815-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。